(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;

(2) child-pugh classification grade a or b；

（3）eastern cooperative oncology group (ecog) performance status score of 2 or less.

advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal)；

tumor invade the inferior vena cava, extrahepatic spread;

contraindications for doxorubicin or oxaliplatin chemotherapy;

any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);

renal failure,cardiac ejection fraction <50 %) or end-stage disease；

patients who were not capable of cooperation during the procedure.